Home / Business and Economy / Sun Pharma Eyes Organon in $12B Pharma Mega-Deal
Sun Pharma Eyes Organon in $12B Pharma Mega-Deal
10 Apr
Summary
- Sun Pharma advances binding $12 billion offer for Organon.
- Deal aims to transform Sun into branded and innovative drug maker.
- Organon faces competition from other global consortiums.
Sun Pharmaceutical Industries is progressing with a binding offer valued at $12 billion for Organon & Co, marking a significant overseas acquisition attempt to become a branded and innovative drug-making leader. The company, led by founder Dilip Shanghvi, has completed over three months of due diligence and is now finalizing a financing package for a firm offer in the coming weeks. JP Morgan is acting as Sun Pharma's financial advisor.
Organon, a US-based company focused on women's health spun off from MSD in 2021, has inherited substantial debt and faces market pressures. Despite this, Sun Pharma's bid is considered a major strategic move. Organon's market capitalization was $1.52 billion as of recently, while Sun Pharma's valuation stands at approximately $44.30 billion. Organon's flagship product, Nexplanon, received an extended five-year usage approval from the FDA in January 2026.
Sun Pharma's chairman has emphasized the need for Indian drugmakers to invest in innovative research and pursue acquisitions for growth. The company has a history of strategic acquisitions, including Checkpoint Therapeutics for up to $416 million. Organon's diverse portfolio includes women's health, biosimilars, and established products. However, Organon is not the sole contender, with other global consortiums also expressing interest in acquiring the company.
